Early Toxicity Testing Market by Technique (In Vivo, In Vitro, and In Silico), and End User (Pharmaceuticals Industry, Food Industry, Chemicals Industry, Cosmetics Industry, and Others): Global Opportunity Analysis and Industry Forecast, 2018–2025
- ALL3201209
- 210 Pages
- May 2019
- Healthcare
The degree of threat posed by a chemical substance to the living organism is defined as toxicity. The branch of science that deals with measurement and further analysis of the adverse effects caused by these chemical substances on the body of an organism is called as toxicology. Toxicity testing of chemical substances is performed to select a potential drug candidate for development of newer molecules. Early toxicity is essential as it is the major reason for the failure of potential drug candidates in the later stages of drug development leading to huge financial loss to companies. Therefore, early toxicity testing is carried out at preclinical stages of a drug development process. Moreover, companies perform early toxicity testing to comply with the government standards to market the drug. There are different techniques such as in vivo, in vitro, and in silico that are employed for testing drug to monitor early toxicity associated with them. Different toxicity tests such as ocular toxicity, carcinogenicity, systemic toxicity, and others are performed using these techniques.
Major factors that drive the market growth are surge in the R&D activities and increase in stringency of regulatory authorities concerning public healthcare welfare. In addition, technological advancements in in vitro techniques, rise in adoption of in vitro models in early toxicity testing industry across the globe, and surge in adoption of early toxicity testing further boost the market growth. However, limitations associated with preclinical testing hamper the market growth. Furthermore, the technological advancements related to early toxicity testing provide lucrative opportunities for the market growth during the forecast period.
This report segments the global early toxicity testing market on the basis of technique, end user, and region to provide a detailed assessment of the market. Based on technique, the market is divided into in vivo, in vitro, and in silico. The market on the basis of in vitro is further divided into in vitro toxicity testing market by assays and in vitro toxicity testing market by toxicity endpoints. The in vitro toxicity testing market by assays is further segmented into enzyme toxicity assays, bacterial toxicity assays, cell-based ELISA & western blots, receptor binding assays, and other assays. The in vitro toxicity testing market by toxicity endpoints is further divided into dermal toxicity, systemic toxicity, carcinogenicity, ocular toxicity, skin sensitization and irritation, neurotoxicity, organ toxicity, and other toxicity endpoints.
On the basis of end user, the market is segmented into pharmaceutical industry, food industry, chemicals industry, cosmetics industry, and other industry. Region wise, the market is studied across different regions such as North America (U.S., Canada and Mexico), Europe (Germany, France, the UK, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa and rest of LAMEA).
KEY BENEFITS FOR STAKEHOLDERS
The study provides an in-depth analysis of the global early toxicity testing market along with the current trends and future estimations to elucidate the imminent investment pockets.
A quantitative analysis from 2017 to 2025 is discussed to enable the stakeholders to capitalize on the prevailing market opportunities.
In-depth analysis of early toxicity testing techniques such as in vivo, in vitro, and in silico is carried out in the report.
The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.
KEY MARKET SEGMENTS
By Technique
• In Vivo
• In Vitro
o In Vitro Toxicity Testing Market by Assays
Enzyme Toxicity Assays
Bacterial Toxicity Assays
Cell-Based ELISA and Western Blots
Tissue Culture Assays
Receptor Binding Assays
Other Assays
o In Vitro Toxicity Testing Market by Toxicity Endpoints
Dermal Toxicity
Systemic Toxicity
Carcinogenicity
Ocular Toxicity
Skin Sensitization and Irritation
Genotoxicity
Neurotoxicity
Organ Toxicity
Other Toxicity Endpoints
o In Silico
By End User
• Pharmaceuticals Industry
• Food Industry
• Chemicals Industry
• Cosmetics Industry
• Other Industries
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o France
o UK
o Rest of Europe
• Asia-Pacific
o India
o China
o Japan
o Australia
o Rest of Asia-Pacific
• LAMEA
o Brazil
o South Africa
o Rest of LAMEA
LIST OF KEY PLAYERS PROFILED IN THE REPORT
• Agilent Technologies, Inc.
• General Electric Company (GE Healthcare)
• Danaher Corporation (Beckman Coulter, Inc.)
• Evotec AG (Cyprotex)
• Bioanalytical Systems, Inc.
• Bruker Corporation
• Thermo Fisher Scientific, Inc.
• PerkinElmer Inc.
• Enzo Biochem, Inc. (Enzo Clinical Labs, Inc.)
• Myriad Genetics, Inc. (Myriad RBM.)
LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request)
• Randox Toxicology
• Geneva Laboratories, Inc.
Advanced Chemistry Development (ACD/Labs)
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.3.1. List of key players profiled in the report
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.3. Top player positioning, 2017
3.4. Porter’s five forces analysis
3.5. Government regulations
3.6. Market dynamics
3.6.1. Drivers
3.6.1.1. Surge in R&D activities in healthcare
3.6.1.2. Rise in adoption of in vitro model
3.6.1.3. Increase in stringency of regulatory authorities concerning public healthcare welfare
3.6.1.4. Surge in adoption of early toxicity testing
3.6.2. Restraint
3.6.2.1. Limitations of preclinical testing
3.6.3. Opportunity
3.6.3.1. Technological advancement in the field of early toxicity testing
3.6.4. Impact analysis
CHAPTER 4: EARLY TOXICITY TESTING MARKET, BY TECHNIQUE
4.1. Overview
4.1.1. Market size and forecast
4.2. In Vivo
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country
4.3. In Vitro
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country
4.3.4. In vitro early toxicity testing market, by assay
4.3.4.1. Enzyme toxicity assays
4.3.4.1.1. Market size and forecast
4.3.4.2. Bacterial toxicity assays
4.3.4.2.1. Market size and forecast
4.3.4.3. Cell-based ELISA and western blots
4.3.4.3.1. Market size and forecast
4.3.4.4. Tissue culture assays
4.3.4.4.1. Market size and forecast
4.3.4.5. Receptor binding assays
4.3.4.5.1. Market size and forecast
4.3.4.6. Others
4.3.4.6.1. Market size and forecast
4.3.5. In vitro early toxicity testing market, by toxicity end-point
4.3.5.1. Dermal toxicity
4.3.5.1.1. Market size and forecast
4.3.5.2. Systemic toxicity
4.3.5.2.1. Market size and forecast
4.3.5.3. Carcinogenicity
4.3.5.3.1. Market size and forecast
4.3.5.4. Ocular toxicity
4.3.5.4.1. Market size and forecast
4.3.5.5. Skin sensitization and irritation
4.3.5.5.1. Market size and forecast
4.3.5.6. Genotoxicity
4.3.5.6.1. Market size and forecast
4.3.5.7. Neurotoxicity
4.3.5.7.1. Market size and forecast
4.3.5.8. Organ toxicity
4.3.5.8.1. Market size and forecast
4.3.5.9. Others
4.3.5.9.1. Market size and forecast
4.4. In silico
4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis, by country
CHAPTER 5: EUROPE EARLY TOXICITY TESTING MARKET, BY END USER
5.1. Overview
5.1.1. Market size and forecast
5.2. Pharmaceutical industry
5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country
5.3. Food industry
5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country
5.4. Chemicals industry
5.4.1. Market size and forecast, by region
5.4.2. Market analysis, by country
5.5. Cosmetic industry
5.5.1. Market size and forecast, by region
5.5.2. Market analysis, by country
5.6. Others
5.6.1. Market size and forecast, by region
5.6.2. Market analysis, by country
CHAPTER 6: EARLY TOXICITY TESTING MARKET, BY REGION
6.1. Overview
6.1.1. Market size and forecast
6.2. North America
6.2.1. Key market trends, growth factors, and opportunities
6.2.2. Market size and forecast, by country
6.2.2.1. U.S.
6.2.2.1.1. U.S. early toxicity testing market, by technique type
6.2.2.1.2. U.S. early toxicity testing market, by end user
6.2.2.2. Canada
6.2.2.2.1. Canada early toxicity testing market, by technique type
6.2.2.2.2. Canada early toxicity testing market, by end user
6.2.2.3. Mexico
6.2.2.3.1. Mexico early toxicity testing market, by technique type
6.2.2.3.2. Mexico early toxicity testing market, by end user
6.2.3. Market size and forecast, by technique type
6.2.4. Market size and forecast, by end user
6.3. Europe
6.3.1. Key market trends, growth factors, and opportunities
6.3.2. Market size and forecast, by country
6.3.2.1. Germany
6.3.2.1.1. Germany early toxicity testing market, by technique type
6.3.2.1.2. Germany early toxicity testing market, by end user
6.3.2.2. France
6.3.2.2.1. France early toxicity testing market, by technique type
6.3.2.2.2. France early toxicity testing market, by end user
6.3.2.3. UK
6.3.2.3.1. UK early toxicity testing market, by technique type
6.3.2.3.2. UK early toxicity testing market, by end user
6.3.2.4. Rest of Europe
6.3.2.4.1. Rest of Europe early toxicity testing market, by technique type
6.3.2.4.2. Rest of Europe early toxicity testing market, by end user
6.3.3. Market size and forecast, by technique type
6.3.4. Market size and forecast, by end user
6.4. Asia-Pacific
6.4.1. Key market trends, growth factors, and opportunities
6.4.2. Market size and forecast, by country
6.4.2.1. Japan
6.4.2.1.1. Japan early toxicity testing market, by technique type
6.4.2.1.2. Japan early toxicity testing market, by end user
6.4.2.2. China
6.4.2.2.1. China early toxicity testing market, by technique type
6.4.2.2.2. China early toxicity testing market, by end user
6.4.2.3. Australia
6.4.2.3.1. Australia early toxicity testing market, by technique type
6.4.2.3.2. Australia early toxicity testing market, by end user
6.4.2.4. India
6.4.2.4.1. India early toxicity testing market, by technique type
6.4.2.4.2. India early toxicity testing market, by end user
6.4.2.5. Rest of Asia-Pacific
6.4.2.5.1. Rest of Asia-Pacific early toxicity testing market, by technique type
6.4.2.5.2. Rest of Asia-Pacific early toxicity testing market, by end user
6.4.3. Market size and forecast, by technique type
6.4.4. Market size and forecast, by end user
6.5. LAMEA
6.5.1. Key market trends, growth factors, and opportunities
6.5.2. Market size and forecast, by country
6.5.2.1. Brazil
6.5.2.1.1. Brazil early toxicity testing market, by technique type
6.5.2.1.2. Brazil early toxicity testing market, by end user
6.5.2.2. South Africa
6.5.2.2.1. South Africa early toxicity testing market, by technique type
6.5.2.2.2. South Africa early toxicity testing market, by end user
6.5.2.3. Rest of LAMEA
6.5.2.3.1. xx early toxicity testing market, by technique type
6.5.2.3.2. rest of LAMEA early toxicity testing market, by end user
6.5.3. Market size and forecast, by technique type
6.5.4. Market size and forecast, by end user
CHAPTER 7: COMPANY PROFILES
7.1. AGILENT TECHNOLOGIES, INC.
7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product type Portfolio
7.1.5. Business performance
7.2. BIOANALYTICAL SYSTEMS, INC.
7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product portfolio
7.2.5. Business performance
7.3. BRUKER CORPORATION
7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Product portfolio
7.3.5. Business performance
7.4. DANAHER CORPORATION (BECKMAN COULTER, INC.)
7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product type portfolio
7.4.5. Business performance
7.5. EVOTEC AG (CYPROTEX)
7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product portfolio
7.5.5. Business performance
7.6. ENZO BIOCHEM, INC. (ENZO CLINICAL LABS, INC.)
7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product Portfolio
7.6.5. Business performance
7.7. GENERAL ELECTRIC COMPANY (GE HEALTHCARE)
7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product portfolio
7.7.5. Business performance
7.8. MYRIAD GENETICS, INC. (MYRIAD RBM.)
7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Product Portfolio
7.8.4. Business performance
7.9. PERKINELMER INC.
7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product Portfolio
7.9.5. Business performance
7.10. THERMO FISHER SCIENTIFIC, INC.
7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Product Portfolio
7.10.5. Business performance
TABLE 01. GLOBAL EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2017–2025 ($MILLION)
TABLE 02. GLOBAL IN VIVO EARLY TOXICITY TESTING MARKET, BY REGION, 2017–2025 ($MILLION)
TABLE 03. GLOBAL IN VITRO EARLY TOXICITY TESTING MARKET, BY REGION, 2017–2025 ($MILLION)
TABLE 04. IN VITRO EARLY TOXICITY TESTING MARKET, BY ASSAYS, 2017–2025 ($MILLION)
TABLE 05. IN VITRO EARLY TOXICITY TESTING MARKET, BY TOXICITY END-POINT, 2017–2025 ($MILLION)
TABLE 06. GLOBAL IN SILICO EARLY TOXICITY TESTING MARKET, BY REGION, 2017–2025 ($MILLION)
TABLE 07. EARLY TOXICITY TESTING MARKET, BY END USER, 2017–2025 ($MILLION)
TABLE 08. EARLY TOXICITY TESTING MARKET FOR PHARMACEUTICAL INDUSTRY, BY REGION, 2017–2025 ($MILLION)
TABLE 09. EARLY TOXICITY TESTING MARKET FOR FOOD INDUSTRY, BY REGION, 2017–2025 ($MILLION)
TABLE 10. EARLY TOXICITY TESTING MARKET FOR CHEMICAL INDUSTRY, BY REGION, 2017–2025 ($MILLION)
TABLE 11. EARLY TOXICITY TESTING MARKET FOR COSMETIC INDUSTRY, BY REGION, 2017–2025 ($MILLION)
TABLE 12. EARLY TOXICITY TESTING MARKET FOR OTHER INDUSTRIES, BY REGION, 2017–2025 ($MILLION)
TABLE 13. EARLY TOXICITY TESTING MARKET REVENUE, BY REGION, 2017–2025 ($MILLION)
TABLE 14. NORTH AMERICA EARLY TOXICITY TESTING MARKET, BY COUNTRY, 2017–2025 ($MILLION)
TABLE 15. U.S. EARLY TOXICITY TESTING MARKET, BY TECHNIQUE TYPE, 2017–2025
TABLE 16. U.S. EARLY TOXICITY TESTING MARKET, BY END USER, 2017–2025
TABLE 17. CANADA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE TYPE, 2017–2025
TABLE 18. CANADA EARLY TOXICITY TESTING MARKET, BY END USER, 2017–2025
TABLE 19. MEXICO EARLY TOXICITY TESTING MARKET, BY TECHNIQUE TYPE, 2017–2025
TABLE 20. MEXICO EARLY TOXICITY TESTING MARKET, BY END USER, 2017–2025
TABLE 21. NORTH AMERICA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE TYPE, 2017–2025
TABLE 22. NORTH AMERICA EARLY TOXICITY TESTING MARKET, BY END USER, 2017–2025
TABLE 23. EUROPE EARLY TOXICITY TESTING MARKET, BY COUNTRY, 2017–2025 ($MILLION)
TABLE 24. GERMANY EARLY TOXICITY TESTING MARKET, BY TECHNIQUE TYPE, 2017–2025
TABLE 25. GERMANY EARLY TOXICITY TESTING MARKET, BY END USER, 2017–2025
TABLE 26. FRANCE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE TYPE, 2017–2025
TABLE 27. FRANCE EARLY TOXICITY TESTING MARKET, BY END USER, 2017–2025
TABLE 28. UK EARLY TOXICITY TESTING MARKET, BY TECHNIQUE TYPE, 2017–2025
TABLE 29. UK EARLY TOXICITY TESTING MARKET, BY END USER, 2017–2025
TABLE 30. REST OF EUROPE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE TYPE, 2017–2025
TABLE 31. REST OF EUROPE EARLY TOXICITY TESTING MARKET, BY END USER, 2017–2025
TABLE 32. EUROPE EARLY TOXICITY TESTING MARKET, BY TECHNIQUE TYPE, 2017–2025
TABLE 33. EUROPE EARLY TOXICITY TESTING MARKET, BY END USER, 2017–2025
TABLE 34. ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY COUNTRY, 2017–2025 ($MILLION)
TABLE 35. JAPAN EARLY TOXICITY TESTING MARKET, BY TECHNIQUE TYPE, 2017–2025
TABLE 36. JAPAN EARLY TOXICITY TESTING MARKET, BY END USER, 2017–2025
TABLE 37. CHINA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE TYPE, 2017–2025
TABLE 38. CHINA EARLY TOXICITY TESTING MARKET, BY END USER, 2017–2025
TABLE 39. AUSTRALIA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE TYPE, 2017–2025
TABLE 40. AUSTRALIA EARLY TOXICITY TESTING MARKET, BY END USER, 2017–2025
TABLE 41. INDIA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE TYPE, 2017–2025
TABLE 42. INDIA EARLY TOXICITY TESTING MARKET, BY END USER, 2017–2025
TABLE 43. REST OF ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY TECHNIQUE TYPE, 2017–2025
TABLE 44. REST OF ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY END USER, 2017–2025
TABLE 45. ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY TECHNIQUE TYPE, 2017–2025
TABLE 46. ASIA-PACIFIC EARLY TOXICITY TESTING MARKET, BY END USER, 2017–2025
TABLE 47. LAMEA EARLY TOXICITY TESTING MARKET, BY COUNTRY, 2017–2025 ($MILLION)
TABLE 48. BRAZIL EARLY TOXICITY TESTING MARKET, BY TECHNIQUE TYPE, 2017–2025
TABLE 49. BRAZIL EARLY TOXICITY TESTING MARKET, BY END USER, 2017–2025
TABLE 50. SOUTH AFRICA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE TYPE, 2017–2025
TABLE 51. SOUTH AFRICA EARLY TOXICITY TESTING MARKET, BY END USER, 2017–2025
TABLE 52. REST OF LAMEA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE TYPE, 2017–2025
TABLE 53. REST OF LAMEA EARLY TOXICITY TESTING MARKET, BY END USER, 2017–2025
TABLE 54. LAMEA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE TYPE, 2017–2025
TABLE 55. LAMEA EARLY TOXICITY TESTING MARKET, BY END USER, 2017–2025
TABLE 56. AGILENT: COMPANY SNAPSHOT
TABLE 57. AGILENT: OPERATING SEGMENTS
TABLE 58. AGILENT: PRODUCT TYPE PORTFOLIO
TABLE 59. BASI: COMPANY SNAPSHOT
TABLE 60. BASI: OPERATING SEGMENTS
TABLE 61. BASI: PRODUCT PORTFOLIO
TABLE 62. BRUKER: COMPANY SNAPSHOT
TABLE 63. BRUKER: OPERATING SEGMENTS
TABLE 64. BRUKER: PRODUCT PORTFOLIO
TABLE 65. DANAHER: COMPANY SNAPSHOT
TABLE 66. DANAHER: OPERATING SEGMENTS
TABLE 67. DANAHER: PRODUCT TYPE PORTFOLIO
TABLE 68. EVOTEC: COMPANY SNAPSHOT
TABLE 69. EVOTEC: OPERATING SEGMENTS
TABLE 70. EVOTEC: PRODUCT PORTFOLIO
TABLE 71. ENZO: COMPANY SNAPSHOT
TABLE 72. ENZO: OPERATING SEGMENTS
TABLE 73. ENZO: PRODUCT PORTFOLIO
TABLE 74. GE HEALTHCARE: COMPANY SNAPSHOT
TABLE 75. GE HEALTHCARE: OPERATING SEGMENTS
TABLE 76. GE HEALTHCARE: PRODUCT PORTFOLIO
TABLE 77. MYRIAD: COMPANY SNAPSHOT
TABLE 78. MYRIAD: PRODUCT PORTFOLIO
TABLE 79. PERKINELMER: COMPANY SNAPSHOT
TABLE 80. PERKINELMER: OPERATING SEGMENTS
TABLE 81. PERKINELMER: PRODUCT PORTFOLIO
TABLE 82. THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT
TABLE 83. THERMO FISHER SCIENTIFIC: OPERATING SEGMENTS
TABLE 84. THERMO FISHER SCIENTIFIC: PRODUCT PORTFOLIO
Similar Reports
The global digital pathology market was valued at $3,323 million in 2016, and is expected to reach $8,668 million by 2023, registering a CAGR of 14.8% during the forecast period. Digital pathology is defined as an image-based information setting enabled b...
- Publish Date: February 26, 2018
- $5370
The global regenerative medicine market was valued at $5,444 million in 2016, and is estimated to reach $39,325 million by 2023, registering a CAGR of 32.2% from 2017 to 2023. Regenerative medicines are used to repair, replace, and regenerate tissues & organs that are affected owin...
- Publish Date: May 29, 2018
- $5370
The medical robotics and computer-assisted surgery is a combination of equipment, accessories, software, and services that aid in performing different functions, such as robotic minimally invasive and non-invasive radiosurgeries, rehabilitation therapies, and hospital & pharmacy automation. Surgical robotics...
- Publish Date: May 1, 2016
- $5370
